Evaluation of the PhaSeal hazardous drug containment system

Hospital Pharmacy

Volumn 34, Issue 11, 1999, Pages 1311-1317

  Sessink, Paul J M ^a   Rolf, Mary Ann E ^b   Rydèn, N Stefan ^b  

^a Exposure Control   (Netherlands)

^b Ängelholms Hospital   (Sweden)

Author keywords

Closed system; Containment device; Cyclophosphamide; Cytostatic drugs; Environmental contamination; Fluorouracil

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; FLUOROURACIL;

CONTAINER; DANGEROUS GOODS; DRUG CONTAMINATION; DRUG SAFETY; DRUG STORAGE; REVIEW; SWEDEN;

EID: 0033494530     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857879903401110     Document Type: Review

References (40)

1. Black DJ, Livingston RB. Antineoplastic drugs in 1990. A review (part 1). Drugs. 1990; 39:489-501.
2. Black DJ, Livingston RB. Antineoplastic drugs in 1990. A review (part 2). Drugs. 1990; 39:652-73.
3. Sorsa M, Hemminki K, Vainio H. Occupational exposure to anticancer drugs -potential and real hazards. Mutat Res. 1985;154:135-149.
4. Ladik CF; Stoehr GP, Maurer MA. Precautionary measures in the preparation of antineoplastics [letter]. Am J Hosp Pharm. 1980; 37:1184-6.
5. McDiarmid M, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med. 1988;30:984-7.
6. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Vol. 26. Some Antineoplastic and Immunosuppressive Agents. Lyon, France: IARC; 1981.
7. International Agency for Research on Cancer. IARC Scientific publications. No. 78. Carcinogenicity ofAlkylating Cytostatic Drugs. Lyon, France: IARC; 1986.
8. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Suppl. 7. Lyon, France: IARC; 1987.
9. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 50. Pharmaceutical Drugs. Lyon, France: IARC; 1990.
10. Baker GL, Kahl LE, Zee BC, et al. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: Long-term case-control follow-up study. Am J Med. 1987; 83:1-9.
11. Greene MH, Harris EL, Gershenson DM, et al. Melphalan may be a more potent leukomogen than cyclophosphamide. Ann Intern Med. 1986;105:360-7.
12. Hemminki K, Kyyrönen P, Lindbohm M-L. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985;39: 141-7.
13. Selevan SG, Lindbohm M-L, Hornung RW, et al. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985;313:1173-8.
14. Valanis BG, Vollmer WM, Labuhn KT et al. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993; 50:455-62.
15. Valanis BG, Vollmer WM, Labuhn KT et al. Acute symptoms associated with antineoplastic drug handling among nurses. Cancer Nurs. 1993;16:288-95.
16. Valanis B, Vollmer W, Labuhn K et al. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997; 39:574-80.
17. Skov T, Maarup B, Olsen J et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992; 49:855-61.
18. Provisions issued by the National Board of Occupational Safety and Health [in Swedish]. Cytostatics. 1984:8. Solna, Sweden.
19. U.S. Department of Labor. 1986. Guidelines for cytotoxic (antineoplastic) drugs (Pub 8-1.1).OSHA, Office of Occupational Medicine; January, 1986.
20. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. AmJ Hosp Pharm. 1990; 47:1033-49.
21. Skov T. Handling antineoplastic drugs in the European Community countries. Eur J Cancer Prev. 1993;2:43-46.
22. Oncology Nursing Society. Cancer Chemotherapy Guidelines on Recommendations for Practice. Pittsburgh., PA: Oncology Nursing Press, Inc; 1996.
23. Comprehensive Cancer Centres. Workbook:Cytostatic Drugs. [in Dutch]. Utrecht, The Netherlands; 1997.
24. Hirst M, Tse S, Mills DG et al. Occupational exposure to cyclophosphamide. Lancet. 1984;1:186-8.
25. Evelo CTA, Bos RP, Peters JGP et al. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health. 1986; 58:151-55.
26. Ensslin AS, Stoll Y, Pethran A et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med. 1994; 51:229-33.
27. Ensslin AS, Huber R, Pethran A et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: Urinary excretion and cytogenetics studies. Int Arch Occup Environ Health. 1997; 70:205-8.
28. Sessink PJM, Boer KA, Scheefhals APH et al. Occupational exposure to antineoplastic agents at several departments in a hospital: Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992;64:105-12.
29. Sessink PJM, Scholtes MM, Anzion RBM et al. Determination of cyclophosphamide in urine by gas chromatography-mass spectrometry. J Chromatogr. 1993;616:333-7.
30. Sessink PJM, van de Kerkhof MCA, Anzion RBM et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: Is skin absorption an important exposure route? Arch Environ Health. 1994;49:165-9.
31. Sessink PJM, Cern· M, Rössner P, et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res. 1994; 309:193-9.
32. Sessink PJM, Kroese ED, van Kranen HJ, et al. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1995;67:317-23.
33. Sessink PJM, Wittenhorst BCJ, Anzion RBM, et al. Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch Environ Health. 1997;52:240-4.
34. Sessink PJM. Monitoring of occupational exposure to antineoplastic agents [thesis]. University of Nijmegen, The Netherlands; 1996. ISBN 90-803205-1.
35. Friberg A. The Protector Project at Sahigrenska University Hospital in Gothenburg [in Swedish]. Sjukhusfarmaci. 1996;2:35-45.
36. FDA approval of PhaSeal system. Model K972527 approved on September 18, 1997 and K980381 approved on March 4, 1998.
37. Test of Closeness of "The Protector System" for Sealed Preparation of Drugs for Parenteral Administration. [in Swedish]. Ref. No. 94K1-0197, Swedish National Testing and Research Institute; October 5, 1994.
38. Sessink PJM, Anzion RBM, van den Broek PHH, et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl. [Sci]. 1992;14:16-22.
39. Council directive of 12 June 1989 on the introduction of measures to encourage improvements in the safety and health of workers at work (89/391/EEC). Official Journal of the European Communities. 1989(June 29);L 183:1-8.
40. Council directive of 28 June 1990 on the protection of workers from the risks related to exposure to carcinogens at work (90/394/EEC). Official Journal of the European Communities. 1990(July 26);L196:1-7.